Highlights

Stock Price Target

 
Search
Recent Price Targets: [Sign In or Register (FREE) to view]
 
KLSE: DPHARMA       DUOPHARMA BIOTECH BHD
Last Price Avg Target Price   Upside/Downside Price Call
1.37 1.58     +0.21 (15.33%)
* Average Target Price, Price Call and Upside/Downside are derived from Price Targets in the past 6 months.
** Price Targets are adjusted for Bonus Issue, Shares Split & Shares Consolidation (where applicable).
Date Open Price Target Price Upside/Downside Price Call Source News
23/05/2019 1.36 1.62 +0.26 (19.12%) BUY TA Price Target News
22/03/2019 1.20 1.61 +0.41 (34.17%) BUY TA Price Target News
08/03/2019 1.14 1.52 +0.38 (33.33%) BUY TA Price Target News
19/02/2019 1.08 1.52 +0.44 (40.74%) BUY TA Price Target News


Price Target Research Article/News (past 6 months)
23/05/2019  TA Duopharma Biotech Berhad - Strong 1Q19 Numbers
22/03/2019  TA Duopharma Biotech Berhad - Expecting FY19 to be a Stronger Year
08/03/2019  TA Duopharma Biotech Berhad - EPO and Oncology the Growth Engines
19/02/2019  TA CCM Duopharma Biotech Bhd - Improved Profitability in 4Q18



  4 people like this.
 
kmwong8711 Today quarter results out??
16/11/2018 10:55 AM
necro I must said recent acquisition & ventures were uninteresting to investor, too many drug & substances in pipeline. Investor dont understand of what is the drug is going to do with Malaysia market.

Asean is not like Singapore, Japan or Korea where the country spend 7% of GDP for healthcare budget, Malaysia for example is only use of 3% GDP for healthcare budget.

Malaysia healthcare priority budgeting only for "3 serangkai" diseases which diabetes, high blood pressure & heart diseases. Disease like autoimmune, chronic kidney disease(ckd), obstetric &, gynaecology using advance medication were too expensive for government to used.

Hopefully CEO does not to eager to pursuing pipeline quantity but focus more on quality, he must realise that that CCMDBIO is conglomerates not science lab where he can test new drug or substances onto Malaysian people.
22/11/2018 9:55 AM
moneytrail Good resukts
28/11/2018 10:56 PM
Tete7893 Luckily run early.
26/12/2018 5:45 PM
Yi Heng 0.94 all in
22/01/2019 7:22 PM
Nicholasming91 Can buy wow
18/02/2019 7:01 PM
Yi Heng yes, dividend 4 sen if approved
18/02/2019 7:23 PM
Investeye CCM Duopharma Biotech Bhd’s fourth quarter net profit rose 18.45% to RM14.37 million from RM12.13 million a year ago, due to higher revenue and changes in accounting policies arising from adoption of the Malaysian Financial Reporting Standards 9 (MFRS 9).
Earnings per share for the quarter ended Dec 31, 2018 rose to 2.17 sen from 1.86 sen.
Quarterly revenue was up 3.01% to RM115.63 million, from RM112.25 million previously, the group said in a filing with Bursa Malaysia.
CCM Duopharma has declared a final dividend of four sen, bringing total payout for FY18 to 5.5 sen, as against 3.64 sen in FY17.
The group has also proposed that the dividend reinvestment plan would apply to the final dividend.
For FY18 as a whole, CCM Duopharma’s net profit increased 12.19% to RM47.64 million or 7.26 sen per share from RM42.46 million or 6.52 sen per share last year, while revenue grew 6.57% to RM498.72 million from RM467.99 million.
On prospects, the group said it sees opportunities from the increase in allocation for health services to RM29 billion in Budget 2019 including RM10.8 billion to restore clinics and hospitals as well to buy medicine and medical equipment.
“The group will also continue its foray into the specialty products as one of its strategies moving forward to create a pool of niche products,” said CCM Duopharma, adding that it has recently received registration approval for Erysaa, an erythropoeitin product.
Barring any unforeseen circumstances, the group expects to achieve satisfactory results in FY19.
18/02/2019 10:08 PM
shpg22 Liquidity has deteriorated quite rapidly, still able to give 4cents dividend. Good management
18/02/2019 10:49 PM
chshzhd good dividend
19/02/2019 10:41 AM
chshzhd but profit improved is due to adoption of MFRS.
19/02/2019 10:45 AM
Yi Heng wait it correction and buy again :)
19/02/2019 12:30 PM
tac2255 finally it gap up
19/02/2019 4:14 PM
LOLANTO what correction.... it's just the very beginning of the rally. buy before it is too late!
19/02/2019 8:20 PM
James Ng https://klse.i3investor.com/blogs/general/194224.jsp
[转贴] [CCM DUOPHARMA BIOTECH BHD:进军特种产品,作为其创建一系列利基产品的战略之一,它最近获得了红细胞生成素产品Erysaa的注册批准] - James的股票投资James Share Investing
20/02/2019 11:52 AM
Investeye SHAH ALAM (Feb 20): CCM Duopharma Biotech Bhd (CCMD) is hopeful of getting its RM10 million goods and services tax (GST) refund from the government within this year.

"We are in the process [of getting the refund]. There are still questions that need to be addressed with the Ministry of Finance (MoF), but we are quite happy with the announcement about the refund. Hopefully, it will be refunded within this financial year," CCMD group managing director Leonard Ariff Abdul Shatar told the press at its extraordinary general meeting (EGM) here.

Last August, Leonard Ariff told The Edge Financial Daily that the government still owed CCMD about RM10 million in GST refunds.
20/02/2019 5:07 PM
factorrumour "A final dividend of 4.0sen/share was proposed (FY18: 5.5sen/share vs. FY17: 3.6sen/share). This translates to a dividend payout ratio of 68%, which is much higher than FY17 payout ratio of 55%."

how did this guy get FY17: 3.6sen/share?
22/02/2019 10:38 PM
factorrumour congrats to all shareholders, a new beginning awaits you all

duopharma biotech!
25/02/2019 10:51 PM
cmshyong when is the ex date for 4 sen dividen?
26/02/2019 7:35 PM
catchcon factorrumour congrats to all shareholders, a new beginning awaits you all

duopharma biotech!

It's good brother, better things to come.
11/03/2019 5:13 AM
chshzhd @factorrumour div for fy17 was 3.6sen bcos the adjustment of bonus issue at june last year
12/03/2019 11:43 AM
chshzhd ..so div 5.5sen for fy18 actually is an improvement of 55% !
12/03/2019 11:45 AM
chshzhd @cmshyong the ex date for 4 sen will be around june this year.
12/03/2019 11:46 AM
Chengkai Kok 目标价:1.52令吉
最新进展:

联合药业(DPHARMA,7148,主板保健股)持续预见大马公共和私人保健领域需求强劲,归功政府增加卫生部拨款。

联合药业去年的销售量仍是大马领先业者;而以销售值来看,从第三名攀升至第二名。

该公司近期取得相关机构批准,出售红血球生成素(EPO)生物仿制药,同时肿瘤设备料于今年第三季推介。

在大马,肿瘤科产品市值高达4亿令吉,所以该利基产品有巨大的机会。

目前本地还未有肿瘤科的设备,该公司计划推出2至3种主要产品来夺得25%市占率(1亿令吉)。

行家建议:

我们预计,联合药业可赢得新的EPO合约、及更新胰岛素合约,并保住市场领导地位。

我国的EPO市场市值达5000万令吉至6000万令吉间,相信该公司有能力与其他供应商竞争,争夺政府大约介于1000万令吉至1500万令吉的合约。

针对今年到期的胰岛素合约,相信该公司可凭借更便宜的价格,延长现有合约2年;若失败,将冲击下财年盈利预测7%。
12/03/2019 1:26 PM
keyin Why no movement,boring
16/03/2019 12:16 PM
Manekineko Hahaha, healthcare counter is like that la... Slow but steady...
18/03/2019 12:32 PM
Dakewlest Moving up. Any TP, anyone?
21/03/2019 6:49 PM
keyin Tp3
21/03/2019 7:15 PM
kmwong8711 For me above 1.30 is good
21/03/2019 7:59 PM
k3nthiew go! go! go!
22/03/2019 9:05 AM
k3nthiew Getting contract soon?
22/03/2019 9:05 AM
Investeye TA Research - 22 Mar 2019 Valuation & Recommendation :
We maintain Buy on Duopharma with a higher TP of RM1.61/share (previously RM1.52/share) based on unchanged 20.0x CY19 PER. We continue to like Duopharma for its: i) strong market share in Malaysia, and ii) move into niche pharmaceuticals products.
22/03/2019 9:41 AM
yapchehhak https://www.theedgemarkets.com/article/insulin-epo-new-products-expected-boost-duopharma-fy19-earnings
26/03/2019 1:05 AM
k3nthiew Push harder please....
28/03/2019 4:20 PM
yapchehhak Slow and steady win the race
29/03/2019 7:31 AM
chshzhd good counter,keep for long term..
29/03/2019 12:35 PM
Manekineko Agree, waiting for next entry point when drop.
03/04/2019 4:38 PM
Dakewlest Any idea for next entry point?
04/04/2019 10:30 AM
Dakewlest Anyone know when are we getting the 4sen dividend?
08/04/2019 10:34 AM
chshzhd last year div ex june
08/04/2019 11:05 AM
Dr Jho Low 42 billion Punter thinking this counter not bad too
08/04/2019 9:35 PM
Dakewlest I bought some this week... may add some more later.
10/04/2019 3:50 PM
Investeye Disposed some to take profit..
10/04/2019 4:54 PM
Investeye Disposed most of the lots as EPF is gradually disposed this counter..
Wait for next wave..
23/04/2019 9:56 AM
Dakewlest Epf acquired last week.
23/04/2019 12:28 PM
Investeye Disposed all DPharma and bank on Pharma. In general, EPF disposed more than acquired..
23/04/2019 4:40 PM
keyin Why EPF do so
23/04/2019 5:37 PM
VinLol123 This counter suitable for long term..
27/04/2019 3:31 PM
YAPSS Day 81 of Fundamental Daily, YAPSS will be covering Duopharma Biotech Berhad's fundamental via a short animated video. I hope it helps and please enjoy the video, see ya! #YAPSS #FundamentalDaily #DuopharmaBiotechBerhad

Click the on the link to find out more: https://youtu.be/wKtLhzvZy_c
25/05/2019 9:28 AM
moneytrail Going for DRP and hold long term! Healthy sales!
22/06/2019 6:39 PM


308  349  511  732 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 ARMADA 0.21+0.005 
 SAPNRG 0.31+0.005 
 HSI-H6Q 0.265-0.01 
 SCOMI 0.08+0.02 
 EKOVEST 0.845-0.01 
 PHB 0.01-0.005 
 GAMUDA 3.57-0.26 
 NICE 0.05+0.02 
 HSI-C5J 0.30-0.01 
 NICE-WB 0.02+0.01 
Partners & Brokers